A state employee raised concerns to a top Florida Medicaid official that the government didn’t follow its standard process in recommending against Medicaid coverage for treatment of gender dysphoria, according to emails included in an ongoing federal lawsuit.
An email from an analyst with the Agency for Health Care Administration said that the state did not “present an honest and accurate assessment” of available research on such treatment, which has been endorsed by major medical groups like the American Academy of Pediatrics, the American Psychological Association and the Endocrine Society.
The emails were included as exhibits in a lawsuit filed in September by a group of health advocacy organizations against the Agency for Health Care Administration challenging a rule, adopted in August, that prohibits transgender Medicaid beneficiaries from getting coverage for gender-affirming treatments, like puberty suppressants and hormone therapies.
